DE3811177A1 - Use of alpha -aminoisocaproic acid (leucine) as active substance for controlling the HIV disease AIDS - Google Patents
Use of alpha -aminoisocaproic acid (leucine) as active substance for controlling the HIV disease AIDSInfo
- Publication number
- DE3811177A1 DE3811177A1 DE19883811177 DE3811177A DE3811177A1 DE 3811177 A1 DE3811177 A1 DE 3811177A1 DE 19883811177 DE19883811177 DE 19883811177 DE 3811177 A DE3811177 A DE 3811177A DE 3811177 A1 DE3811177 A1 DE 3811177A1
- Authority
- DE
- Germany
- Prior art keywords
- leucine
- controlling
- alpha
- hiv disease
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 5
- BRHPBVXVOVMTIQ-JEDNCBNOSA-N (2s)-2-amino-4-methylpentanoic acid;2-amino-4-methylpentanoic acid Chemical compound CC(C)CC(N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-JEDNCBNOSA-N 0.000 title claims 2
- 208000031886 HIV Infections Diseases 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960003136 leucine Drugs 0.000 abstract description 9
- 239000003797 essential amino acid Substances 0.000 abstract description 3
- 235000020776 essential amino acid Nutrition 0.000 abstract description 3
- 235000019454 L-leucine Nutrition 0.000 abstract description 2
- 239000004395 L-leucine Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Bei der Behandlung der durch das HIV-Virus verursachten Erkrankung AIDS ist die Problematik bisher die, daß das Virus durch ein Medikament nicht direkt angegriffen und zerstört werden kann, ohne zugleich andere Körperzellen zu schädigen (z. B. Azidothymidin kurz AZT genannt). Ein Ausweg aus dieser Situation ist nur dann möglich, wenn der Körper mit dem Virus selbst fertig wird.In the treatment of by the HIV virus AIDS is the problem so far the that the virus through a drug not be attacked and destroyed directly can without other body cells at the same time damage (e.g. azidothymidine abbreviated AZT). The only way out of this situation is then possible if the body with the virus itself is finished.
Es hat sich gezeigt, daß die essentielle Amino säure L-Leucin die Fähigkeit besitzt, in hoher Blut- und Plasmakonzentration das HIV-Virus zu zerstören. Leucin bricht die Disulfid-Brücken des Cystins an bestimmten Stellen des HIV-Genoms auf -SS- und lagert sich endständig an die entstandenen Polypeptidketten an. Dieser Vorgang ist beim HIV-Virus nicht reversibel, das Virus stirbt ab, die entstehenden hochmolekularen Ketten werden größtenteils über den Urin ausgeschieden und stellen einen guten Parameter dar für den Verlauf der Heilung.It has been shown that the essential amino acid L-leucine has the ability in high Blood and plasma levels increase the HIV virus to destroy. Leucine breaks the disulfide bridges of cystine at certain locations in the HIV genome on -SS- and finally attaches itself to the resulting polypeptide chains. This process is not reversible with the HIV virus, the virus the resulting high molecular chains die are largely excreted in the urine and are a good parameter for the Course of healing.
Einen analogen wenn auch nicht völlig entsprechen den und geklärten Effekt erzielt die Aminosäure Lysin bei einer Infektion mit Herpesviren (Dr. Michael Colgan "Ihr persönliches Vitamin profil", Hestia-Verlag, S. 162).An analog, if not completely, match The amino acid achieves the clarified effect Lysine in a herpes virus infection (Dr. Michael Colgan "Your personal vitamin profil ", Hestia-Verlag, p. 162).
Der Vorteil der Verwendung von Leucin bei der Be kämpfung von HIV im Gegensatz zu den bisher einge setzten Medikamenten liegt darin, daß es sich um eine essentielle Aminosäure handelt, die im Gegen satz zu anderen Medikamenten nicht toxisch ist und bis auf gelegentlich bei disponierten Personen auftretenden Hypoglykämien bei oraler Applikation keine Nebenwirkungen aufweist. Diese Nebenwirkung ist durch Zufuhr von Glucose und Übergang auf parenterale Applikation zu beherrschen.The advantage of using leucine in loading fighting HIV in contrast to the previously used put medication is that it is an essential amino acid that acts in the opposite is not toxic to other drugs and except occasionally for people who are scheduled Hypoglycaemia occurring with oral administration none Has side effects. This side effect is through Intake of glucose and transition to parenteral Master application.
Die Zufuhr von Eiweißstoffen aller Art, Aminosäuren und Aminosäuregemischen muß während der Behandlung mit Leucin unterbleiben, da andere Aminosäuren, insbe sondere Arginin einen proliferierenden Effekt auf die Virusentwicklung besitzen.The supply of all kinds of proteins, amino acids and amino acid mixtures must be treated with No leucine, because other amino acids, esp special arginine a proliferating effect on the Possess virus development.
Die Behandlung erfolgt zweckmäßigerweise durch Dauer tropfinfusion, wobei handelsübliche Glucose und sterili sierte Leucinlösungen zu verwenden sind. Sie erstreckt sich je nach Zustand des Patienten über einen Zeitraum von 3-7 Tagen. Die medikamentöse Behandlung von etwaigen opportunistischen Erkrankungen kann weitergeführt werden.The treatment is expediently carried out by duration drip, with commercial glucose and sterile based leucine solutions are to be used. It stretches depending on the patient's condition over a period of time from 3-7 days. Drug treatment of any opportunistic diseases can be continued.
Die nach kurzer Zeit (1-3 Tagen) auftretende Protein urie, meist hochmolekulare Proteine, läßt das Ansprechen auf die Behandlung erkennen und stellt ein sicheres An zeichen für die beginnende Heilung dar, wenn die Protein konzentration im Urin noch während der Behandlung zurück geht.The protein that appears after a short time (1-3 days) urie, mostly high molecular weight proteins, leaves the response Recognize the treatment and make sure Signs of healing beginning when the protein concentration in the urine during treatment goes.
Außerdem ist keine Gewöhnung an das Leucin möglich, bei einer etwaigen Neuinfektion ist die Behandlung in gleicher Weise möglich.In addition, it is not possible to get used to the leucine any new infection is treatment in possible in the same way.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19883811177 DE3811177A1 (en) | 1988-03-31 | 1988-03-31 | Use of alpha -aminoisocaproic acid (leucine) as active substance for controlling the HIV disease AIDS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19883811177 DE3811177A1 (en) | 1988-03-31 | 1988-03-31 | Use of alpha -aminoisocaproic acid (leucine) as active substance for controlling the HIV disease AIDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3811177A1 true DE3811177A1 (en) | 1989-10-19 |
Family
ID=6351265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19883811177 Withdrawn DE3811177A1 (en) | 1988-03-31 | 1988-03-31 | Use of alpha -aminoisocaproic acid (leucine) as active substance for controlling the HIV disease AIDS |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3811177A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004175732A (en) * | 2002-11-28 | 2004-06-24 | Masami Moriyama | Therapeutic agent for retroviral infectious disease |
| WO2011151685A1 (en) * | 2010-06-03 | 2011-12-08 | Raouf Rekik | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament |
-
1988
- 1988-03-31 DE DE19883811177 patent/DE3811177A1/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004175732A (en) * | 2002-11-28 | 2004-06-24 | Masami Moriyama | Therapeutic agent for retroviral infectious disease |
| JP4554149B2 (en) * | 2002-11-28 | 2010-09-29 | 雅美 森山 | Retroviral infection treatment |
| WO2011151685A1 (en) * | 2010-06-03 | 2011-12-08 | Raouf Rekik | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hunter et al. | Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication | |
| Tartara et al. | Vigabatrin in the treatment of epilepsy: a double‐blind, placebo‐controlled study | |
| ATE515265T1 (en) | VITAMIN D AND ITS ANALOGUES FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATIVE DISEASES | |
| ATE204178T1 (en) | METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN | |
| DE69230112D1 (en) | ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE | |
| DE69209414T2 (en) | Preparations that promote brain activity | |
| DE69021415T2 (en) | Agents for the treatment of senile dementia, memory disorders and similar conditions. | |
| EP0345247A2 (en) | Use of monosubstitute selenium compounds in the preparation of a pharmaceutical, pharmaceutical and preparation thereof | |
| Tamizi et al. | Treatment of gingival lichen planus with a free gingival graft: a case report. | |
| DE69231036T2 (en) | METHOD FOR TREATING PATIENTS WITH CHRONIC LIVER DISEASE | |
| DE3811177A1 (en) | Use of alpha -aminoisocaproic acid (leucine) as active substance for controlling the HIV disease AIDS | |
| DE1917283C3 (en) | Manufacture of antimicrobial preparations | |
| EP0402208B1 (en) | Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect | |
| Hemmingsen et al. | Hypnagogic and hypnopompic hallucinations during amitriptyline treatment | |
| DE4317331A1 (en) | Treatment of impairments of the immune system | |
| DE69921678D1 (en) | COMPOSITION CONTAINING DI- AND TRINATRIUM SALTS OF ECHINOCHROME FOR THE TREATMENT OF EYE DISEASES | |
| DE3234061C2 (en) | ||
| DE69431430D1 (en) | Factor XIII for the treatment of skin wounds | |
| EP0278013B1 (en) | Anti-hypoxical medicine | |
| DE2740953A1 (en) | USE OF PROSTAGLANDINES TO LOWER BLOOD SUGAR LEVELS | |
| DE69113437T2 (en) | Therapeutic agents for diabetic gangrene. | |
| AT504041A1 (en) | USE OF THE ENZYMATIC REMOVAL OF ENDOGENOUS OPIOID NEUROPEPTIDES INHIBITOR SUBSTANCES | |
| EP1156830A2 (en) | Oil-in-water emulsion for the use as medicament or for producing a medicament | |
| DE69618511T2 (en) | Gamma interferon-containing composition for prurigo treatment | |
| RU2078559C1 (en) | Method of parodontosis treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: HAJEK, ERNST, 8014 NEUBIBERG, DE |
|
| 8141 | Disposal/no request for examination |